Cargando…
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1
Myotonic dystrophy type 1 (DM1) is one of the most common muscular dystrophies and can be potentially treated with antisense therapy decreasing mutant DMPK, targeting miRNAs or their binding sites or via a blocking mechanism for MBNL1 displacement from the repeats. Unconjugated antisense molecules a...
Autores principales: | Stoodley, Jessica, Vallejo-Bedia, Francisco, Seone-Miraz, David, Debasa-Mouce, Manuel, Wood, Matthew J. A., Varela, Miguel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916419/ https://www.ncbi.nlm.nih.gov/pubmed/36769018 http://dx.doi.org/10.3390/ijms24032697 |
Ejemplares similares
-
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
por: González-Martínez, Irene, et al.
Publicado: (2023) -
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021) -
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
por: Overby, Sarah J., et al.
Publicado: (2022) -
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
por: Klein, Arnaud F., et al.
Publicado: (2019) -
Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1
por: De Serres-Bérard, Thiéry, et al.
Publicado: (2022)